Ironwood Pharmaceuticals Inc (IRWD)

IRWD (NASDAQ:Drugs) EQUITY
$15.11
pos +0.00
+0.00%
Today's Range: 15.04 - 15.43 | IRWD Avg Daily Volume: 999,500
Last Update: 04/24/15 - 3:59 PM EDT
Volume: 0
YTD Performance: -1.40%
Open: $0.00
Previous Close: $15.48
52 Week Range: $9.90 - $17.11
Oustanding Shares: 141,160,332
Market Cap: 1,948,667,695
6-Month Chart
TheStreet Ratings Grade for IRWD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 1 1 2 3
Moderate Buy 0 0 0 0
Hold 6 6 4 3
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 2
Mean Rec. 3.00 3.00 2.71 2.75
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -11.13
Price Earnings Comparisons:
IRWD Sector Avg. S&P 500
-11.13 0.00 28.22
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-5.48% 25.77% 17.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue 234.10 0.16 0.05
Net Income 0.00 1.92 0.00
EPS 0.00 1.14 0.00
Earnings for IRWD:
EBITDA -0.16B
Revenue 0.08B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $-0.22 $-0.18 $-0.58 $0.24
Number of Analysts 8 8 8 8
High Estimate $-0.18 $-0.10 $-0.05 $1.78
Low Estimate $-0.27 $-0.23 $-0.88 $-0.29
Prior Year $-0.38 $-0.38 $-1.33 $-0.58
Growth Rate (Year over Year) 41.45% 52.96% 56.39% 141.81%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

bullishIronwood upgraded at Cantor

Feb 6, 2015 | 7:43 AM EST

IRWD was upgraded form Sell to Hold, Cantor Fitzgerald said. Company lacks negative near-term catalysts. $13.50 price target. 

By

Bret Jensen

 | Dec 12, 2014 | 10:00 AM EST

Synergy Pharmaceuticals is developing drugs to treat gastrointestinal disorders and diseases. The

bearishIronwood downgraded at Cantor

Nov 6, 2014 | 6:54 AM EST

IRWD was downgraded from Hold to Sell, Cantor Fitzgerald said. $10 price target. Valuation call, as the company will likely spend more on R&D in the new year. 

bullishIronwood upgraded at Cantor

Jul 24, 2013 | 7:51 AM EDT

IRWD was upgraded to Hold, Cantor Fitzgerald said. $10 price target. Linzess can continue to grow and the company is keeping a tight lid on costs. 

bullishIronwood upgraded at Wedbush

May 30, 2013 | 8:09 AM EDT

IRWD was upgraded from Underperform to Neutral, Wedbush said. $12 price target. Linzess prescriptions are growing.

By

Gary Dvorchak

 | Apr 26, 2013 | 11:00 AM EDT

The negative surprises indicate hidden weakness in a business, and the stocks are to be avoided.

bearishIronwood Pharmaceutical downgraded at Wedbush

Apr 24, 2013 | 8:17 AM EDT

Shares of IRWD were downgraded to Underperform  from Neutral, said Wedbush. Cash burn is occurring much faster than expected given high R&D expenses. Price target is $12.

bullishIronwood Pharmaceuticals upgraded at Credit Suisse

Mar 15, 2013 | 8:18 AM EDT

IRWD was upgraded to Outperform, Credit Suisse said. $24 price target. Expect higher Linzess sales. 

bullishIronwood Pharmaceutical upgraded at Wedbush

Feb 13, 2013 | 8:38 AM EST

IRWD was upgraded to Neutral from Underperform, Wedbush said. $13 price target. LINZESS strong out of the gates. 

bearishIronwood Pharmaceutical downgraded at UBS

Jan 16, 2013 | 8:39 AM EST

IRWD was downgraded to Sell from Neutral, UBS said. $11.50 price target. Expectations too high. 

A gravetone doji candle formed on the weekly Facebook (FB) chart. This candle is defined b...
The iPath Bloomberg Sugar SubTR ETN (SGG) is pushing up towards a test of its prior rally ...
We added some call plays on Microsoft and Celgene today on the very strong price action (m...
Juniper Networks is the number three gainer in the S&P 500 today(behind Amazon/Mi...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.